Circulating chemerin decreases in response to a combined strength and endurance training

Abstract

Chemerin is an adipokine that may mediate the link between obesity, inflammation, insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. In this study, we examined the association between chemerin and various cardiometabolic risk factors in cross-sectional setting and tested the hypothesis that a 6-month combined exercise program decreases serum chemerin in overweight or obese, non-diabetic individuals. Serum chemerin concentration was measured in a cross-sectional analysis including 98 individuals with a wide range of age and body mass index (BMI). In addition, chemerin was measured in 79 sedentary, overweight or obese, non-diabetic individuals who completed a 6-month combined endurance and resistance exercise program (CEP, n = 51) or served as controls (C, n = 28). Chemerin was significantly associated with total cholesterol (p = 0.04), triglycerides (p < 0.001), fasting insulin (p < 0.001), homeostasis model assessment of insulin resistance (HOMA-IR, p < 0.001), systolic blood pressure (p = 0.04), highly sensitive C-reactive protein (p = 0.03), leucocytes count (p = 0.047), and leptin (p = 0.008) independently of age and BMI. In multiple regression analysis, chemerin was an independent determinant of HOMA-IR. As a result of the 6-month training program, serum chemerin decreased significantly in CEP group (-13.8 ± 13.2 ng/ml, p < 0.001). A significant association between the changes in chemerin and improved HOMA-IR were found even after adjustment for changes in waist circumference. Among non-diabetic individuals serum chemerin was associated with various cardiometabolic risk factors independently of BMI. In addition, the 6-month combined strength and endurance training program led to a significant reduction in circulating chemerin levels in overweight or obese individuals.

Effect of an acute bout of aerobic exercise on chemerin levels in obese adults

“…Additionally, two recent studies observed associations between changes in chemerin and improvements in insulin sensitivity following chronic exercise interventions. Stefanov et al (2014) found decreases in serum chemerin following a 6-month endurance and resistance training regimen to be associated with concomitant decreases in HOMA-IR. Likewise, Kim et al (2013) observed a correlation between decreases in serum chemerin and improvements in the insulin sensitivity index following a 12-week lifestyle modification program which also included both aerobic and resistance exercise.…”

Effect of Irbesartan on Chemerin in the Renal Tissues of Diabetic Rats

“…The levels of chemerin, an adipokine identified fairly recently, were correlated with body mass index (BMI) and components of the metabolic syndrome in normal and overweight subjects [5,[7][8][9][10][11][12][13][14][15][16][17][18][19]. It has also been shown that the levels of chemerin in patients with metabolic syndrome are significantly correlated with BG, high density lipoprotein-cholesterol (HDL-C), CHOL, TG, CRP, fasting insulin and the homeostatic model assessment (HOMA) index [18,[20][21][22], whereas a negative correlation exists with the glomerular filtration rate (GFR) [23]. Studies also indicate that serum chemerin levels are significantly elevated in patients on chronic hemodialysis and are correlated with renal function [7].…”

Chemerin Elicits Potent Constrictor Actions via Chemokine‐Like Receptor 1 (CMKLR1), not G‐Protein‐Coupled Receptor 1 (GPR1), in Human and Rat Vasculature

“…High blood pressure could be a potential link given that it contributes both to metabolic syndrome and is a major risk factor for cardiovascular disease. Circulating chemerin concentration positively correlates with both systolic and diastolic blood pressure in a range of patient populations, particularly those with obesity, metabolic syndrome, type 2 diabetes mellitus, and type 2 diabetes mellitus with hypertension, and these patient groups are at higher risk of developing cardiovascular disease. Our data show, for the first time, that chemerin causes concentration‐dependent contraction of human blood vessels and has a direct effect on blood pressure in rats by binding to CMKLR1 on the smooth muscle layer.…”